Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research VEGF 

    • The role of VEGF across tumor types 

    • VEGF in gastric cancer 

    • Regulation of VEGF expression 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
    • Research B cell
    • Research BRAF
    • Research HDIs
    • Research HER Pathways
    • Research MET
    • Research VEGF
      • Why is the VEGF ligand essential throughout tumor development?
      • What are the strategies for inhibiting the VEGF pathway?
      • What are the effects of direct VEGF ligand inhibition?
      • Why is continued VEGF inhibition important?
      • Why do tumors progress?
      • The role of VEGF across tumor types
        • VEGF in lung cancer
        • VEGF in colorectal cancer
        • VEGF in renal cell carcinoma
        • VEGF in glioblastoma
        • VEGF in ovarian cancer
        • VEGF in bladder cancer
        • VEGF in gastric cancer
          • VEGF expression in gastric cancer
          • Regulation of VEGF expression
          • Serum VEGF as a clinical marker
          • VEGF and tumor progression in gastric cancer
          • VEGF, MVD, and metastases in gastric carcinoma
          • Summary
        • VEGF in multiple myeloma
        • VEGF in pancreatic cancer
      • Slide decks and videos
      • Glossary
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Tumor Types
    • Colorectal Cancer
      • Colorectal Cancer
    • Glioblastoma
      • Glioblastoma
    • Lung Cancer
      • Lung Cancer
    • Ovarian Cancer
      • Ovarian Cancer
    • Pancreatic Cancer
      • Pancreatic Cancer
    • Renal Cell Carcinoma
      • Renal Cell Carcinoma
  • Molecular Causes of Cancer
    • Angiogenesis
      • Inducing angiogenesis
    • Growth Signaling
      • Evading growth suppressors
    • Tissue Invasion and Metastasis
      • Activating invasion and metastasis
  • Biological Pathways
    • Angiogenic Signaling
      • Angiogenic Signaling
    • Apoptotic Signaling
      • Apoptosis
    • Bcell Surface Proteins
      • B-cell Surface Proteins
    • HER Signaling
      • HER Signaling
    • MAPK Signaling
      • MAPK Signaling
  • Therapeutic Targets
    • BCL-2
      • Bcl-2
    • HER1
      • HER1
    • HER2
      • HER2
    • HER3
      • HER3
    • HER4
      • HER4
    • VEGF
      • VEGF
  • Clinical Trials
    • Gastric Cancer
      • Gastric Cancer
  • Future Directions
    • Antibody-Drug conjugates
      • A brief history of ADCs
      • Current research in ADCs
      • Cytotoxic agent
      • VEGF expression in gastric cancer
      • HER Signaling
      • High VEGF expression
      • How are ADCs designed to work?
      • VEGF and prognosis in multiple myeloma
      • Glossary
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • Monoclonal antibody
      • Multimedia Resources
      • Receptor-Mediated Endocytosis
      • Research ADCs
      • VEGF, MVD, and metastases in gastric carcinoma
      • Stable linker
      • Targeting cancers with ADCs
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
      • What are ADCs?
    • Glycoengineered Antibodies
      • VEGF expression in gastric cancer
      • HER Signaling
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF, MVD, and metastases in gastric carcinoma
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Non-Antibody Biologics
      • Apoptosis
      • VEGF expression in gastric cancer
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF, MVD, and metastases in gastric carcinoma
      • VEGF expression in multiple myeloma
      • What are the strategies for inhibiting the VEGF pathway?
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Targeted Small Molecules
      • Apoptosis
      • VEGF expression in gastric cancer
      • Gastric Cancer
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • Glossary
      • VEGF expression and liver metastases
      • MAPK Signaling
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF, MVD, and metastases in gastric carcinoma
      • PI3K/Akt/mTOR Signaling
      • Slide decks and videos
      • VEGF expression in multiple myeloma
      • What are the strategies for inhibiting the VEGF pathway?
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Traditional Monoclonal Antibodies
      • B-cell Surface Proteins
      • Glossary
      • VEGF expression in gastric cancer
      • Gastric Cancer
      • HER Signaling
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF, MVD, and metastases in gastric carcinoma
      • Angiogenic Signaling
      • Slide decks and videos
      • VEGF expression in multiple myeloma
      • What are the strategies for inhibiting the VEGF pathway?
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma

Video

Full VEGF & angiogenesis

View video now

Links

  • VEGF in NSCLC
  • VEGF in CRC
  • VEGF in RCC
  • VEGF in GBM
  • VEGF in ovarian cancer
  • VEGF in bladder cancer
  • VEGF in multiple myeloma
  • VEGF in pancreatic cancer
Share

VEGF Expression Regulation in Gastric Cancer

The multitude of growth factors expressed by gastric cancer cells produce effects via autocrine and paracrine pathways. VEGF released by tumor cells induces neovascularization within carcinoma tissue, promoting angiogenesis and the progression of gastric carcinomas, particularly those of the intestinal subtype.1 As in other malignancies, high VEGF expression is one of the characteristic features of gastric carcinomas.2

VEGF in the autocrine loop1

VEGF in the autocrine loop

VEGF is one of the growth factors released by gastric cancer cells that form a feedback loop to the cancer cells, and also induces angiogenesis in endothelial cells.


Reprinted with permission from Smith MG, Hold GL, Tahara E, et al. World J Gastroenterol. 2006;12:2979-2990. Figure 5.

References:
1.
Smith MG, Hold GL, Tahara E, et al. World J Gastroenterol. 2006;12:2979-2990. PMID: 16718776
2.
Kösem M, Tuncer I, Kotan Ç, et al. Hepatogastroenterology. 2009;56:1236-1240. PMID: 19760978
 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: Serum VEGF as a clinical marker »

© 2011 Genentech USA, Inc. All rights reserved